Mayo Clinic Ventures

Submit a New Inquiry

Technology #2015-196 - BET Inhibitors Sensitize Cancer Cells to PARP Inhibitors

Mayo Clinic Ventures contracts with Nouvant to provide this service.

Your inquiry will be sent to this technology's managers. All fields are required unless otherwise noted.



By submitting this inquiry you accept the terms of the Privacy Policy and Terms of Service.

Powered by Nouvant